Authors:
Mohmmad M. Alawajneh1†, Waseem Sameer1†, Mohamed Al Zobi1, Eesha A. Zaheer2, Ravi Talati3, Harry Lesmana3,4*
1 Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
2 Cleveland Clinic Foundation, Department of Pediatrics, Pediatric Institute, Cleveland, OH, USA
3 Cleveland Clinic Foundation, Department of Pediatric Hematology, Oncology, and BMT, Pediatric Institute, Cleveland, OH, USA
4 Cleveland Clinic Foundation, Center for Personalized Genetic Healthcare, Medical Specialty Institute, Cleveland, OH, USA
These authors contributed equally to this work and share the first authorship
  1. Mohmmad M. Alawajneh, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan, Email: mmalawajneh183@med.just.edu.jo, ORCID iD: 0000-0002-9563-8060
  2. Waseem Sameer, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan, Email: waseemsameermd@outlook.com, ORCID iD: 0009-0008-3325-863
  3. Mohamed Al Zobi, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan, Email: mhamadzohbe99@gmail.com, ORCID iD: 0009-0001-9826-7621
  4. Eesha A. Zaheer, Cleveland Clinic Foundation, Department of Pediatrics, Pediatric Institute, Cleveland, OH, USA, Email: zaheere2@ccf.org, ORCID iD: 0003-1376-0968
  5. Ravi Talati, Cleveland Clinic Foundation, Department of Pediatric Hematology, Oncology, and BMT, Pediatric Institute, Cleveland, OH, USA, Email: talatir@ccf.org , ORCID iD: 0009-0007-9514-6828
  6. Harry Lesmana* Cleveland Clinic Foundation, Center for Personalized Genetic Healthcare, Medical Specialty Institute, Cleveland, OH, USA Cleveland Clinic Foundation, Department of Pediatric Hematology, Oncology, and BMT, Pediatric Institute, Cleveland, OH, USA Email: lesmanh@ccf.org, ORCID iD: 0000-0001-5496-3839
* Corresponding Author
Word Count for the main text: 853
The number of Tables, Figures, and Supporting Information files: two; one table and one figure.
Running title: Evans Syndrome Management in 22q11.2D Syndrome.
Keywords: Evans Syndrome, TPO-RA, romiplostim, 22q11.2 deletion syndrome, Immune cytopenia
Consent for Publication : Written informed consent for publication of this case series was obtained from the parental guardian of the described pediatric patients.
Author Contribution: All authors participated in the design and conception. Mohmmad M. Alawajneh, Waseem Sameer, Mohmmad Al Zobi, Eesha A. Zaheer participated in drafting the manuscript. Waseem Sameer made the figure. Ravi Talati and Harry Lesmana supervised the work. All authors have participated in editing and reviewing the final version of the manuscript, read it, and agreed to publish it.
Disclosures : The authors declare no competing interests.
This paper has been previously presented as a poster titled “IMMUNE CYTOPENIAS IN 22Q11.2 DELETION SYNDROME” at The American Society of Pediatric Hematology/Oncology Annual Meeting (ASPHO 2023) in MAY 2023 in Fort Worth, Tx. The abstract was published in Volume 70, issue S3 of the Pediatric Blood and Cancer Journal in June 2023.